[go: up one dir, main page]

LV11618B - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
LV11618B
LV11618B LVP-96-31A LV960031A LV11618B LV 11618 B LV11618 B LV 11618B LV 960031 A LV960031 A LV 960031A LV 11618 B LV11618 B LV 11618B
Authority
LV
Latvia
Prior art keywords
paroxetine hydrochloride
propan
bound
solvate
anhydrous
Prior art date
Application number
LVP-96-31A
Other languages
English (en)
Latvian (lv)
Other versions
LV11618A (lv
Inventor
Victor Witold Jacewicz
Neal Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV11618(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of LV11618A publication Critical patent/LV11618A/xx
Publication of LV11618B publication Critical patent/LV11618B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-96-31A 1995-02-06 1996-02-02 Novel compounds LV11618B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (2)

Publication Number Publication Date
LV11618A LV11618A (lv) 1996-12-20
LV11618B true LV11618B (en) 1997-04-20

Family

ID=27267578

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-31A LV11618B (en) 1995-02-06 1996-02-02 Novel compounds

Country Status (47)

Country Link
EP (3) EP1136490B1 (fr)
JP (2) JP2915338B2 (fr)
KR (1) KR100289885B1 (fr)
CN (3) CN1090187C (fr)
AR (2) AR001982A1 (fr)
AT (1) AT407528B (fr)
AU (2) AU4786496A (fr)
BE (1) BE1009112A3 (fr)
BG (1) BG62967B1 (fr)
BR (1) BR9600534A (fr)
CA (4) CA2168829C (fr)
CH (3) CH689804A5 (fr)
CZ (1) CZ297171B6 (fr)
DE (3) DE69631298T2 (fr)
DK (2) DK11996A (fr)
DZ (1) DZ1989A1 (fr)
ES (1) ES2114471B1 (fr)
FI (3) FI111544B (fr)
FR (1) FR2730232B1 (fr)
GR (1) GR1002466B (fr)
HK (1) HK59397A (fr)
HU (1) HUP9600255A1 (fr)
IE (1) IE80500B1 (fr)
IL (1) IL117035A (fr)
IT (1) IT1289532B1 (fr)
LU (1) LU88711A1 (fr)
LV (1) LV11618B (fr)
MA (1) MA23802A1 (fr)
MC (1) MC2411A1 (fr)
MX (1) MX9600484A (fr)
MY (1) MY132529A (fr)
NL (1) NL1002248C2 (fr)
NO (3) NO301009B1 (fr)
NZ (1) NZ280943A (fr)
OA (1) OA10261A (fr)
PL (1) PL189247B1 (fr)
PT (1) PT101827B (fr)
RO (1) RO112426B1 (fr)
RU (1) RU2125052C1 (fr)
SE (1) SE521084C2 (fr)
SG (1) SG43787A1 (fr)
SI (2) SI21923B (fr)
SK (1) SK283608B6 (fr)
TR (1) TR199600096A2 (fr)
TW (1) TW503238B (fr)
UA (1) UA49796C2 (fr)
WO (1) WO1996024595A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (fr) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Procédé de séchage pour le chlorhydrate de paroxetine
JP2000514653A (ja) * 1996-07-15 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 立体特異的分割のためのエステラーゼのスクリーニングおよびその使用
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (fr) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Forme utile de chlorhydrate de paroxetine anhydre
ES2155995T3 (es) * 1997-06-10 2001-06-01 Synthon Bv Compuestos de 4-fenilpiperidina.
PT903345E (pt) * 1997-08-08 2001-01-31 Aventis Pharma Gmbh Forma cristalina de n-(4-trifluorometilfenil)-5-metil-isoxazolo-4-carboxamida
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
EA200000946A1 (ru) * 1998-03-16 2001-02-26 Смитклайн Бичам Плс Кристаллическая форма пароксетина
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
JP3796351B2 (ja) 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
PL345885A1 (en) * 1998-08-07 2002-01-14 Smithkline Beecham Plc Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
ES2211232T3 (es) * 1998-11-30 2004-07-01 Smithkline Beecham Plc Solvatos mixtos de paroxetina-propan-2-ol.
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
ATE311883T1 (de) * 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
WO2002022609A1 (fr) * 2000-09-14 2002-03-21 Asahi Glass Company, Limited Procede de production de sel de paroxetine sensiblement exempt de solvant organique
CA2476723A1 (fr) * 2002-02-22 2003-09-04 Gideon Pilarski Preparation de paroxetine impliquant de nouveaux intermediaires
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
CA2096853A1 (fr) * 1990-11-24 1992-05-25 Anthony Michael Johnson Emploi de la paroxetine pour le traitement de la demence senile, de la boulimie, de la migraine ou de l'anorexie
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
AT407528B (de) 2001-04-25
CH688353A5 (de) 1997-08-15
CA2210023A1 (fr) 1996-08-07
HU9600255D0 (en) 1996-03-28
IL117035A (en) 2000-02-29
EP0808314A1 (fr) 1997-11-26
IL117035A0 (en) 1996-09-12
DE19603797A1 (de) 1996-08-14
CN1636993A (zh) 2005-07-13
JPH11228571A (ja) 1999-08-24
WO1996024595A1 (fr) 1996-08-15
MC2411A1 (fr) 1996-12-02
MX9600484A (es) 1997-01-31
RU2125052C1 (ru) 1999-01-20
ITMI960203A0 (fr) 1996-02-05
NO970939D0 (no) 1997-02-28
NO311519B1 (no) 2001-12-03
CN1090187C (zh) 2002-09-04
TW503238B (en) 2002-09-21
NO301009B3 (fr) 2003-01-06
CN1143643A (zh) 1997-02-26
FI111544B (fi) 2003-08-15
SE521084C2 (sv) 2003-09-30
UA49796C2 (uk) 2002-10-15
JPH08245620A (ja) 1996-09-24
OA10261A (en) 1997-09-19
KR960031409A (ko) 1996-09-17
PT101827B (pt) 1997-08-29
NO20015070D0 (no) 2001-10-18
GR1002466B (el) 1996-11-06
CA2168829A1 (fr) 1996-08-07
EP1136490A1 (fr) 2001-09-26
HUP9600255A1 (en) 1997-03-28
ATA21096A (de) 2000-08-15
FI20030162L (fi) 2003-02-03
CA2211522A1 (fr) 1996-08-07
BR9600534A (pt) 1997-05-13
NO301009B1 (no) 1997-09-01
NO970939L (no) 1996-08-07
AU701518C (en) 2006-12-07
MA23802A1 (fr) 1996-10-01
CH689804A5 (de) 1999-11-30
RO112426B1 (ro) 1997-09-30
FI20030162A7 (fi) 2003-02-03
SK283608B6 (sk) 2003-10-07
AR036856A2 (es) 2004-10-06
ES2114471A1 (es) 1998-05-16
SI9600036A (en) 1996-10-31
AR001982A1 (es) 1998-01-07
IT1289532B1 (it) 1998-10-15
NL1002248A1 (nl) 1996-08-06
SI21923B (sl) 2006-12-31
BG100333A (bg) 1996-08-30
IE80500B1 (en) 1998-08-12
SG43787A1 (en) 1997-11-14
AU4786496A (en) 1996-08-27
FI960519L (fi) 1996-08-07
FI20030370L (fi) 2003-03-12
PL189247B1 (pl) 2005-07-29
SE9600406L (sv) 1996-08-07
DE69631298D1 (de) 2004-02-12
FI20030370A7 (fi) 2003-03-12
NL1002248C2 (nl) 1996-09-11
DE69631298T2 (de) 2004-11-18
FR2730232A1 (fr) 1996-08-09
AU701518B2 (en) 1999-01-28
LU88711A1 (fr) 1996-08-23
CA2168829C (fr) 1997-12-16
CA2210022A1 (fr) 1996-08-07
MY132529A (en) 2007-10-31
SI21923A (sl) 2006-06-30
CZ297171B6 (cs) 2006-09-13
EP1378508A1 (fr) 2004-01-07
LV11618A (lv) 1996-12-20
NO960472D0 (no) 1996-02-05
CH689229A5 (de) 1998-12-31
JP2915338B2 (ja) 1999-07-05
KR100289885B1 (ko) 2001-05-15
TR199600096A2 (tr) 1996-08-21
BE1009112A3 (fr) 1996-11-05
IE960104A1 (en) 1996-08-07
CN1289496C (zh) 2006-12-13
EP1136490B1 (fr) 2004-01-07
DE19603797C2 (de) 1998-11-12
NO960472L (no) 1996-08-07
CN1216055C (zh) 2005-08-24
BG62967B1 (bg) 2000-12-29
CZ32096A3 (en) 1996-08-14
CA2210022C (fr) 2005-09-13
FI960519A0 (fi) 1996-02-05
DE69621777D1 (de) 2002-07-18
NO20015070L (no) 1996-08-07
AU4332896A (en) 1996-08-15
FR2730232B1 (fr) 1997-08-01
CN1310180A (zh) 2001-08-29
HK59397A (en) 1997-05-16
SE9600406D0 (sv) 1996-02-05
CA2211522C (fr) 1999-12-07
SI9600036B (sl) 2006-12-31
PT101827A (pt) 1996-09-30
EP0808314B1 (fr) 2002-06-12
SK14396A3 (en) 1996-11-06
PL312646A1 (en) 1996-08-19
ITMI960203A1 (it) 1997-08-05
DK200100223A (fr) 2001-02-12
ES2114471B1 (es) 1999-08-16
NZ280943A (en) 1997-01-29
DE69621777T2 (de) 2003-01-02
CA2210023C (fr) 1999-02-09
MX198371B (fr) 2000-08-29
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15

Similar Documents

Publication Publication Date Title
LV11618B (en) Novel compounds
US6133289A (en) Paroxetine hydrochloride form A or C
NZ509180A (en) Paroxetine Methanesulfonate
MXPA04007995A (es) Desolvatacion de solvatos de hemicalcio de atorvastatina.
CY2015A (en) Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AU740561B2 (en) Paroxetine hydrochloride anhydrate
EP1135383B1 (fr) Solvates de paroxetine propan-2-ol melanges
CA2211521A1 (fr) Nouveaux composes de paroxetine hydrochlorine anhydrate
WO2000078752A1 (fr) Procede de production de chlorhydrate de paroxetine